Cat. No. 4646
Alternative Name: GF 120918
Chemical Name: N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-
Biological ActivityP-glycoprotein (P-gp/ABCG1) inhibitor. Blocks P-gp-mediated multidrug resistance (MDR) of the cytotoxic drugs doxorubicin (Cat. No. 2252) and vincristine (Cat. No. 1257) in CHRC5 cells. Also inhibits breast cancer resistance protein (BCRP/ABCG2). Orally active.
Licensing InformationSold for research purposes under agreement from GlaxoSmithKline.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Myer et al (1999) The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line. Oncol Rep. 6 217. PMID: 9864431.
Hyafil et al (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53 4595. PMID: 8402633.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Elacridar hydrochloride include:
Jablonski et al (2014) Inhibiting drug efflux transporters improves efficacy of ALS therapeutics. Ann Clin Transl Neurol 1 996. PMID: 25574474.
Do you know of a great paper that uses Elacridar hydrochloride from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Elacridar hydrochloride, supplier, GF120918, P-glycoprotein, P-gp, inhibitors, inhibits, multidrug, resistance, MDR, BCRP, ABCG1, ABCG2, ABCB1, Tocris Bioscience, Multidrug Transporter Inhibitor products